Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671 · eVOLVECervical Phase 3Recruiting
- Lead sponsor
- AstraZeneca (Industry)
- Enrollment
- 800 (estimated)
- Start date
- 22 Sep 2023
- Primary completion
- 26 Nov 2027 (estimated)
- Study completion
- 30 Sep 2030
- Last update posted
- 30 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Volrustomig Biological
- Placebo Other
Conditions and primary outcome
- Locally Advanced Cervical Cancer
Primary outcome
Progression-free Survival (PFS) based on the investigator assessment in all randomized participants (FAS) (Up to approximately 7 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06079671.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06079671 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.